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The contribution of decameric vanadate species to vanadate toxic eﬀects in cardiac muscle was studied following an intravenous
administration of a decavanadate solution (1 mM total vanadium) in Sparus aurata. Although decameric vanadate is unstable in the
assay medium, it decomposes with a half-life time of 16 allowing studying its eﬀects not only in vitro but also in vivo. After 1, 6 and
12 h upon decavanadate administration the increase of vanadium in blood plasma, red blood cells and in cardiac mitochondria and cyto-
sol is not aﬀected in comparison to the administration of a metavanadate solution containing labile oxovanadates. Cardiac tissue lipid
peroxidation increases up to 20%, 1, 6 and 12 h after metavanadate administration, whilst for decavanadate no eﬀects were observed
except 1 h after treatment (+20%). Metavanadate administration clearly diﬀers from decavanadate by enhancing, 12 h after exposure,
mitochondrial superoxide dismutase (SOD) activity (+115%) and not aﬀecting catalase (CAT) activity whereas decavanadate increases
SOD activity by 20% and decreases (55%) mitochondrial CAT activity. At early times of exposure, 1 and 6 h, the only eﬀect observed
upon decavanadate administration was the increase by 20% of SOD activity. In conclusion, decavanadate has a diﬀerent response pattern
of lipid peroxidation and oxidative stress markers, in spite of the same vanadium distribution in cardiac cells observed after decavanadate
and metavanadate administration. It is suggested that once formed decameric vanadate species has a diﬀerent reactivity than vanadate,
thus, pointing out that the diﬀerential contribution of vanadium oligomers should be taken into account to rationalize in vivo vanadate
toxicity.
 2006 Elsevier Inc. All rights reserved.
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Several biological studies associate vanadium with the
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E-mail address: maalves@ualg.pt (M. Aureliano).in antioxidant enzymes alterations and leading to lipid per-
oxidation [1–8]. The involvement of toxic metals in cardiac
oxidative damage suggests that this organ shows a great
vulnerability to metal intoxication [9–12]. Notwithstand-
ing, and despite the magnitude of the knowledge so far
accumulated, the biochemical basis for the observed
in vivo oxidative eﬀects of vanadium in cardiac tissue are
still poorly deﬁned.
Most of toxicological vanadate studies in biology do
not take into consideration the contribution of vanadate
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the vanadate solutions also contains several vanadate
oligomers besides the monomeric vanadate (V1), such as
dimeric (V2) and tetrameric (V4) vanadate species. Fur-
thermore, decameric vanadate species (V10), which are
formed upon medium acidiﬁcation, are well known to
aﬀect the activity of several enzymes [13–15]. It has been
suggested that V10 decomposition is slow enough to allow
studying its eﬀects in biochemical systems [16,17], not only
in vitro but also in vivo [16–21]. More recently, it was
described that V10 can be stabilized upon interaction with
cytoskeleton and membrane proteins [22]. Therefore, we
cannot exclude the hypothesis that V10 may also occur at
physiological conditions for long enough to induce diﬀer-
ent biological eﬀects in comparison to metavanadate. If
V10 would occur at physiological conditions, does it induce
speciﬁc eﬀects in vivo? Are these eﬀects diﬀerent from the
ones promoted by metavanadate? Does V10 also contrib-
ute to the toxicity induced by vanadate? Once formed
in vivo, does decavanadate prevent the eﬀects induced by
metavanadate?
To our knowledge, very few in vivo studies with V10
have been published so far. Since 1999, our group has per-
formed in vivo administration of decavanadate in order to
understand the contribution of V10 to the toxic eﬀects of
vanadate [16–21]. A metavanadate solution not containing
V10 was also administered as a comparison group of study,
besides a placebo group. Until now, following in vivo
administration of V10, several parameters were analysed
such us: subcellular vanadium distribution; lipid peroxida-
tion; antioxidants enzymes activities besides several oxida-
tive stress markers. Among the diﬀerent experimental
conditions described, it was included diﬀerent: mode of
V10 administration (intraperitoneal, i.p. versus intrave-
nous, i.v.); animal species (Halobatrachus didactylus and
Sparus aurata); vanadate concentration (5 mM); tissues
(cardiac, hepatic, renal, blood); subcellular fractions (cyto-
sol, mitochondria, red blood cells, blood plasma); exposure
time (12 and 24 h, 2 and 7 days). Therefore, besides the
interest of piscine models to oxidative stress studies, being
more sensitive to heavy metals toxicity than mammals, it
has been shown to be very useful to study decavanadate
toxicity, since at the ﬁsh physiological temperature deca-
meric vanadate species is stable enough to induce diﬀerent
eﬀects than vanadate itself.
In the present work, we report the most relevant ﬁndings
both with mitochondrial and cytosolic cardiac subcellular
fractions following V10 in vivo administration at early
exposure times (1, 6 and 12 h) and for sublethal concentra-
tion (1 mM total vanadium) of two vanadate solutions
(decavanadate and metavanadate) intravenously injected
in Sparus aurata (gilthead seabream). For early times of
exposure and lower vanadate concentration, in vivo V10
administration was found to induce a diﬀerent pattern of
ROS production and lipid peroxidation and diﬀerent
changes on superoxide dismutase and catalase activities
than metavanadate.2. Material and methods
2.1. Vanadate solutions
Metavanadate stock solution (50 mM, pH 6.7) was pre-
pared from ammonium metavanadate purchased from Rie-
del-de-Hae¨n. Decavanadate stock solution was obtained by
adjusting the pH of the former solution to 4.0 [23]. Deca-
vanadate stock solutions were always adjusted to pH about
7.0 immediately before using; being both deca and meta-
vanadate solutions diluted to the ﬁnal concentration
(1 mM) in physiological solution (0.9% NaCl) and kept
on ice before use. Whereas the metavanadate solution is
stable, an estimate half-life time of 16 h was estimated for
decameric species that partially deoligomerizes in the injec-
tion medium (0.9% NaCl), in agreement with our previous
reports [16,17].
2.2. NMR measurements
The vanadate oligomers present in decavanadate and
metavanadate solutions used on the study of vanadium
in vivo eﬀects on oxidative stress responses were measured
by 51V Nuclear Magnetic Resonance spectroscopy in a
Bruker AM-400 spectrometer at 105.2 MHz equipped with
a 5 mm multinuclear inverse probe, by using a 90 pulse
Fourier transform technique. Spectra were acquired at
room temperature using 0.5 ml of vanadate samples in
the injection medium (0.9% NaCl) or in the presence of
5% blood plasma, containing at least 10% D2O, under
the following conditions: spectral width 45455 Hz, accu-
mulation time 0.05 s and relaxation delay 0.01 s. Chemical
shift values are given with reference to VOCl3 (0 ppm) as a
standard. The relative areas of the several free and bound
vanadate resonances were integrated and the line widths
were obtained after subtracting the value (20 Hz) used in
line broadening. The concentration of vanadate oligomers
Vx was calculated from the fractions of the total integrated
areas observed in the recorded spectra as described (Eq.
(1)). The symbol A corresponds to the area measured for
the x vanadate species with the n aggregation number
(number of vanadium atoms), At the sum of measured
areas and [Vt] corresponds to total vanadate concentration.
V x½  ¼ AxAt 
V t½ 
n
: ð1Þ
The calculated concentrations of vanadate oligomers
were reproducible within 2–4%. For quantitative measure-
ments all spectra parameters were kept constant.
2.3. Animals and treatments: in vivo studies
Gilthead seabream (Sparus aurata), weighing 400–600 g
were obtained from a local ﬁsh-farm at the Algarve region,
south coast of Portugal. Fish were maintained in 450 L
tanks, in aerated and recirculating seawater, under con-
trolled conditions (20 C, 35& and exposed to natural
Table 1
Reactive oxygen species (ROS), superoxide dismutase (SOD), catalase
(CAT) and lipid peroxides (thiobarbituric reactive species – TBARS)
basal/control values in cardiac tissue of Sparus aurata
Basal/control values
Mitochondrial overall ROS
production
384 ± 140 a.u./min/mg protein
Mitochondrial SOD activity 20091 ± 6951 U/mg protein
Mitochondrial CAT activity 1.63 ± 0.51 nmol/min/
mg protein
Lipid peroxidation 3.02 ± 0.51 lMTBARS/g tissue
Values are presented as means ± SD (n = 3).
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During adaptation to laboratory conditions, ﬁsh were daily
fed ad libitum with commercial ﬁsh pellets and were starved
for 2 days, before sacriﬁced with anaesthetic overdosage of
2-fenoxiethanol (bath). For in vivo assays: 54 individuals
were divided in three groups (Placebo, Deca and Meta
groups) and treated with an intravenous (i.v.) injection of
1 ml/kg of 0.9% NaCl or 1 mM vanadium, as decavanadate
or metavanadate, respectively; sub-groups of six individu-
als were sacriﬁced 1, 6 and 12 h after injection, respectively.
Simultaneously, at the beginning of the experiment, a con-
trol group (n = 6) was sacriﬁced to determine basal values
(Table 1).
Blood samples were collected by direct puncture of the
caudal vein and placed on heparin at 4 C. The blood sam-
ples were centrifuged at 500g for 10 min, in order to isolate
red blood cells (RBC) from plasma (the leukocyte and
upper erythrocyte layers were removed).2.4. Mitochondrial and cytosolic subcellular fractions
isolation
To obtain mitochondrial and cytosolic fractions, the
heart was immediately removed after blood collection,
weighted; and the ventricle excised. Ventricular muscle was
weighted, freshly minced into small pieces, placed in ice-cold
0.5 M sucrose containing 20 mM Tris (tris(hydroxy-
methyl)aminomethane) pH 7.6, 0.15 M KCl, 1 mM EDTA
(ethylenediaminetetraacetic acid) and 1 mM DTT (dithio-
threitol) and homogenized in an Ultra-Turrax, for three
periods of 30 s at full speed, in 10 ml of the same sucrose
medium per gram of sample tissue. Mitochondrial and
cytosolic cardiac muscle subcellular fractions were prepared
according to the procedure described elsewhere [16]. Protein
content was determined by Bradford method [24] using the
Sigma protein dye reagent and bovine serum albumin
(BSA) as protein standard.2.5. Subcellular vanadium distribution
Subcellular vanadium distribution analysis of cardiac
tissue (cytosolic and mitochondrial fractions) and blood
(plasma and RBC) samples was performed as previousdescribed [21]. Brieﬂy, after drying, digestion and re-sus-
pension, vanadium content of the residue was determined
by atomic absorption spectroscopy (AAS) using a GBC
Avanta atomic absorption spectrometer, equipped with a
GBC GF 3000 graphite furnace system, with a GBC
PAL 3000 auto sampler, working at a furnace program
of 63 s with an argon gas ﬂow of 3.0 L/min. The vanadium
lamp was operated at 318.2 nm, with slit width of 0.2 nm
and the instrument was calibrated against a series of solu-
tions containing 5, 10, 15 and 20 ppb of vanadium. Cali-
brating standards were obtained by successive dilutions
of a Merck standard solution of vanadium 1002 ± 2 mg/
L. The detection and quantiﬁcation limits of the instrument
for these analysis conditions, determined according ISO
8466-1, were 5 ± 1 and 14 ± 3 ppb, respectively.
TORT-2, lobster hepatopancreas marine reference
material for trace metals (certiﬁed vanadium content
1.64 ± 0.19 mg vanadium/kg), was purchased from
National Research Council of Canada. Accuracy of the
method was determined through analysis of the certiﬁed
reference material TORT-2. Vanadium recovery ranged
from 106% to 115% of the certiﬁed value. Precision was
also acceptable, with 10% relative standard deviation, for
this method.2.6. Reactive oxygen species (ROS) production assay
The overall rate of ROS production in cardiac mito-
chondria was determined from the kinetics of increasing
of ﬂuorescence (kexc = 495 nm, kem = 520 nm) of the probe
dichlorodihydroﬂuorescein diacetate (H2DCFDA) [8,25].
Fluorescence measurements were carried out under contin-
uous stirring at 25 C with a Perkin–Elmer 650-40 Fluores-
cence Spectrophotometer. The assay was performed, in a
medium containing 50 mM KH2PO4 (pH 7.0), 100 mM
KCl and 2 ng/ml H2DCFDA and was started after sample
addition.2.7. Superoxide dismutase and catalase activities
Antioxidant responses in cardiac mitochondrial fraction
of S. aurata were determined evaluating changes in antiox-
idant enzymes activities by UV–visible spectroscopy in a
Hitachi Spectrophotometer. The catalase (CAT) activity
was determined in mitochondrial fraction using the direct
determination of hydrogen peroxide consumption at
240 nm, as previously described [26], in a medium contain-
ing 50 mM KH2PO4/K2HPO4 pH 7.0 and 50 mM H2O2.
The superoxide dismutase (SOD) activity was evaluated
in mitochondrial fraction with the xanthine oxidase–cyto-
chrome-c method modiﬁed as described elsewhere [16] in
a reaction medium containing 50 mM KH2PO4/K2HPO4
pH 7.8, 0.1 mM EDTA, 10 lM cytochrome-c, 50 lM xan-
thine and suﬃcient xanthine oxidase to produce a rate of
reduction of cytochrome-c at 550 nm of 0.025 absorbance
unit per min.
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The evaluation of free radical-induced damage in lipid
membranes of ﬁsh heart was determined by analysis of
lipid peroxidation. The evidence of lipid membrane oxida-
tion was performed monitoring the thiobarbituric acid-
reactive substances (TBARS) formation in the total
homogenate of heart tissue, as described elsewhere [16,27].
2.9. Statistical analysis
All parameters studied are present as averages and stan-
dard deviation of measurements taken from six individuals
in each group. Statistical signiﬁcance of the data was per-
formed using Mann–Whitney non-parametric test. Diﬀer-
ences from controls were considered signiﬁcant at P < 0.05.
For all parameters analysed, the groups control and
placebo showed no-signiﬁcant diﬀerences between them
(P > 0.05) and therefore these two groups were considered
together (Control group) for results analysis and
presentation.
3. Results and discussion
3.1. Characterization of vanadate solutions
Since most of the vanadate species can be detected by
51V NMR spectroscopy, it was observed that the spectraFig. 1. 105.2 MHz 51V NMR spectra, at room temperature, of decavanadate (
vanadium). All spectra were acquired in the presence of 10% D2O.of decavanadate stock solution, 50 mM in total vanadium,
at pH 7.0, contained mainly decameric species once the
three signals from decameric vanadate species, ascribed
to the three vanadium atoms of the decavanadate structure
[28], are observed: V10A at 517 ppm, V10B at 501 ppm,
V10C at 426 ppm and a weak signal (V1) at 562 ppm
(Fig. 1A). On the other hand, in the metavanadate
stock solutions, 50 mM total vanadium concentration,
were detected monomeric (V1), dimeric (V2), tetrameric
(V4) and also pentameric (V5) species, respectively, at
561 ppm, 575 ppm, 579 ppm and at 587 ppm
(Fig. 1B), as described elsewhere [23].
In vanadium(V) solutions, diﬀerent oligomeric (n = 1–
10) vanadate species can occur simultaneously in equilib-
rium, e.g., monomeric (V1), dimeric (V2), tetrameric (V4)
and decameric (V10) and, in same cases, with diﬀerent
states of protonation and conformations (Fig. 2). The pre-
dominant species are dependent of pH, concentration and
ionic strength [29]. Methods for the preparation of vana-
date solutions containing only monomeric or decameric
species have been developed to test the eﬀects promoted
by these species [14,19]. Decavanadate stock solutions con-
tain only decameric vanadate species but when it does dis-
integrates the monomeric vanadate (V1) also appears in
solution (Fig. 2). Metavanadate solutions contain both
monovanadate (V1) and also metavanadate species such
as V2 and V4 cyclic (Fig. 2). Decameric vanadate species
(responsible for the orange colour of the vanadatepH 4.0) (A) and metavanadate (pH 6.7) (B) stock solutions (50 mM total
Fig. 2. Vanadate oligomers can occur simultaneously in equilibrium in
aqueous solutions. Vanadate oligomers: V1, monomeric deprotonated and
monoprotonated (HV1); V2, dimeric; V4, tetrameric cyclic; V10, deca-
meric. Decavanadate (responsible for the orange colour of the vanadate
solutions) could be decomposed into monomeric vanadate (colourless
solutions) whereas metavanadate solutions (yellow or colourless depend-
ing upon vanadate concentration) contain labile oxovanadates in rapid
equilibrium such as V1, V2 and V4 (cyclic). In the representation of some
oligomeric vanadate species, vanadium atoms (black spheres), oxygen
atoms (open circles) and hydrogen atoms (small open circles) are used.
(Adapted from Refs. [28,29].)
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(colourless solutions) whereas metavanadate solutions (yel-
low or colourless depending upon vanadate concentration)
contain labile oxovanadates in rapid equilibrium such as
V1, V2 and V4 (Fig. 2).
After dilution of the decavanadate solution into the
injection medium (NaCl 0.9%) in the concentration nor-
mally used in the present studies (1 and 5 mM in vana-
dium), the concentration of decameric vanadate increases
linearly with total vanadate concentration whereas mono-
meric vanadate does not (Fig. 3A), as described recently
[22]. In fact, the concentrations of each vanadate oligomer
calculated by integration of the respective areas of the
NMR spectra, as a function of total vanadate, exhibit dif-
ferent proﬁles according to the species. This was also
observed upon dilution of the metavanadate solution into
the injection medium, in the concentration range normally
used in biochemical studies, diﬀerent concentrations of
mono-(V1); di-(V2); tetra-(V4) and pentameric-(V5) species
are present, being the higher molecular vanadate oligomers
favoured by increasing total vanadate concentration
(Fig. 3B). For example, nominal 1 mM metavanadate, in
addition to about 500 lM monomeric (V1), also contains
83 lM dimeric (V2) and 84 lM tetrameric (V4) species.
In the presence of 5% blood plasma in the dilution med-
ium, neither the concentration of the diﬀerent vanadate
species nor the ratio between vanadate oligomers in both
solutions were changed. However, for 10% of blood plasma
NMR signals become barely detectable, likely due to a
large broadening of the peaks and pointing out to vana-
date/protein interactions (not shown).
Conversely to metavanadate, the decavanadate solution
is unstable in the assay medium as analysed by UV–visible
spectroscopy (Fig. 4, inset graphic). In contrast to the labile
oxovanadates present in the metavanadate solutions
(Fig. 2), which interconvert on the time scale of millisec-
onds to seconds, decameric vanadate has a very slow
decomposition kinetics upon dilution (Fig. 4). When deca-
meric vanadate species present in decavanadate solutions(Fig. 2) completely decomposes into monomeric vanadate
species (V1) which solutions are colourless, also the
UV–visible spectra changes from the one described for
the decavanadate solution to the one described for the
metavanadate solution (Fig. 4, inset graphic). The kinetics
of decomposition of decameric species followed by UV–vis-
ible spectroscopy, at 25 C, in the saline solution used for
in vivo administration, assessed by measurements of the
absorption at 400 nm conﬁrms a ﬁrst-order kinetic process
(Fig. 4), with an half-life time of 16 h (measured with 1 mM
total vanadate concentration, i.e., 100 lM decameric vana-
date species). After this time, the NMR spectra contain not
only decameric vanadate species but also the others species
present in metavanadate solutions, in agreement to
described elsewhere [14,19,23]. Therefore, the NMR spec-
tra of the decavanadate solution 16 h upon dilution, is a
mixed of the spectra of Fig. 1A and B. This complex oxo-
anion remains relatively stable at room temperature, allow-
ing studying its eﬀects not only in vitro but also in vivo.
Moreover, it was recently described that decameric vana-
date stabilization by cytoskeletal and transmembrane pro-
teins can account, at least in part, for decavanadate eﬀects
in biological systems [22].
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administration
The amount of vanadium in Sparus aurata cardiac tissue
(46 ± 11 ng/g dry tissue) and blood (231 ± 45 ng/g dry
tissue), are within the range of values reported for ﬁsh
[16,30,31]. The basal vanadium content in heart is about
10 times lower than the value reported for hepatic tissue [20].
After intravenous (i.v.) administration of vanadate solu-
tions, the highest amount of vanadium was found in blood
plasma 1 h after exposure (5484 ± 1483 and 4111 ± 467
ng/g dry tissue in individuals exposed to metavanadate
and decavanadate, respectively), being about 1000-fold
higher than in red blood cells (RBC) (291 ± 78 and
380 ± 135 ng/g dry tissue in individuals exposed to meta-
vanadate and decavanadate, respectively) (Fig. 5). After 6
and 12 h, the amount of vanadium in plasma decreases to
about 4000 and 2000 ng/g dry tissue, respectively, for both
vanadate solutions. In fact, it has been described that the
binding of vanadium to plasma proteins is of special inter-
est, as the vanadium binding proteins can play a role in the
transport of vanadium in blood. Transferrin and albumin
have been reported to be binding proteins for vanadium
in human plasma [32]. In RBC, 12 h after vanadate i.v.
administration, individuals intoxicated with metavanadate
exhibits a higher concentration of vanadium (966 ±
454 ng/g dry tissue), relatively to those injected with deca-
vanadate (320 ± 67 ng/g dry tissue) (Fig. 5).
Regarding cardiac mitochondria and cytosol, lower
amounts of vanadium (<100 ng/g dry tissue) were found
upon vanadate in vivo administration, not changing with
exposure time in cytosol (about 50 ng/g dry tissue) for both
solutions, while in mitochondria the amount of vanadium
after the ﬁrst hour (about 45 ng/g dry tissue) is about half
of the vanadium content at 6 and 12 h, for both solutions.Apparently, 1 mM decavanadate does not aﬀect vanadium
distribution at the earlier times since similar values were
observed for metavanadate.
Previous works done with higher vanadate concentra-
tion (5 mM) for the same ﬁsh species showed a tendency
to vanadium accumulation in mitochondria upon deca-
vanadate i.v. administration in comparison to cytosol,
being accumulated 2-fold higher in mitochondria in the
cardiac tissue and for the same exposure time [31]. On con-
trary, for the same concentration (5 mM) and diﬀerent
mode of administration (intraperitoneal, i.p.), it was not
observed the tendency of vanadium to accumulate in car-
diac mitochondria upon decavanadate i.p. administration
in H. didactylus (toadﬁsh) [16]. Putting it all together, the
distribution of vanadium in cardiac mitochondria, follow-
ing decameric vanadate administration depends on total
vanadium concentration and mode of administration. This
ﬁnding is in agreement with the fact that vanadium subcel-
lular distribution is dependent on the way of administra-
tion [33].
For the same mode of administration (i.v.) used in the
present study but for other tissue (liver) it has also been
described that vanadium accumulation is favoured in hepa-
tic mitochondria (2-fold higher than in cytosol), 24 h upon
5 mM decavanadate i.v. injection in H. didactylus [20]. The
general tendency is that both liver and cardiac mitochon-
dria may be a vanadium intracellular target. Apparently,
for both tissues, the vanadium accumulation in mitochon-
dria is favoured upon V10 administration.
3.3. Lipid peroxidation
It was observed that 1 h upon i.v. administration, car-
diac tissue lipid peroxidation increases to the same extent
for both vanadate solutions (Fig. 6). The lipid peroxidation
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decavanadate or metavanadate i.v. administration, both
vanadate solutions increased (P < 0.05) the basal value
3.02 ± 0.51 lmol MDA/g tissue (Table 1) by about 20%,
being this eﬀect maintained after 6 and 12 h only formetavanadate (Fig. 5). It has been described, for higher
vanadate concentration (5 mM), diﬀerent mode of adminis-
tration (i.p.), longer exposure times, diﬀerent ﬁsh species
(H. didactylus), but for the same tissue (heart) a signiﬁcant
increase (P < 0.05) in cardiac tissue lipid peroxidation
propagation only 7 days after i.p. administration in H.
didactylus (about 80% and 60% upon decavanadate and
metavanadate, respectively) [16].
In liver tissue from a diﬀerent ﬁsh species, higher vana-
date concentration (5 mM) but for the same way of admin-
istration used in the present study (i.v.) an 80% increase
(P < 0.05) in lipid peroxidation was observed 24 h after
i.v. administration of both vanadate solutions in H.
didactylus [20]. In that study, decameric vanadate does
not promotes signiﬁcant changes 12 h after administration,
in agreement to the results obtained in the present study,
whereas metavanadate increased lipid peroxidation prod-
ucts by about 55% (P < 0.05). However, 24 h after i.v.
administration the lipid peroxidation value is similar to
metavanadate-administered individuals (80%) [31]. There-
fore, for higher (5 mM) decavanadate concentrations a
delayed time eﬀect in lipid peroxidation is observed for
decavanadate in comparison to metavanadate.
For lower concentrations of vanadate (1 mM) both solu-
tions induced lipid peroxidation, but once again the eﬀects
reveal to be diﬀerent and dependent on the time after
S.S. Soares et al. / Journal of Inorganic Biochemistry 101 (2007) 80–88 87administration (Fig. 6). It is suggested that decameric van-
adate species induce peroxidation due to a diﬀerent reactiv-
ity or even prevent the eﬀects promoted by metavanadate
since it does not maintain the levels exhibited by metavana-
date, 6 and 12 h after exposure. Eventually, after adminis-
tration, the total decomposition of decameric species into
metavanadate would not induce the same eﬀects observed
for the latter solution. Probably, the interactions promoted
by the labile oxovanadates are diﬀerent from the ones
induced by decameric vanadate. Moreover, by the time
that V10 would totally decompose into other vanadate
oligomers the targets may not be the same in order to
induce the same eﬀects as before.3.4. Oxidative stress markers
The overall prooxidant activity upon vanadate exposure
was determined by quantitative analysis of reactive oxygenR
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Fig. 7. Overall rate of reactive oxygen species (ROS) production variation
in cardiac mitochondria of Sparus aurata. Deca and meta, refer to
decavanadate and metavanadate (1 mM total V, 1 ml/kg) groups, respec-
tively. Variation is calculated based on basal values (Table 1). Values are
present as means ± SD (n = 6). * Signiﬁcantly diﬀerent from control
(P < 0.05).
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Fig. 8. Superoxide dismutase (SOD) (A) and catalase (CAT) (B) activity vari
refer to decavanadate and metavanadate (1 mM total V, 1 ml/kg) groups, respe
present as means ± SD (n = 6). * Signiﬁcantly diﬀerent from control (P < 0.05species (ROS) production and shows that, in ﬁsh heart
mitochondria, only metavanadate induces a signiﬁcant
and delayed increase (P < 0.05) in ROS production
(Fig. 7). The basal value for prooxidant activity in cardiac
tissue 384 ± 140 a.u./min/mg protein (Table 1) increased
above 198% (P < 0.05), 12 h after metavanadate adminis-
tration, whereas no signiﬁcant eﬀects were observed for
decavanadate (Fig. 7). In agreement with the increase in
ROS production, metavanadate induced an increase
(+115%) in mitocondrial superoxide dismutase (SOD)
activity (P < 0.05), 12 h after exposure, while decavanadate
increased about 30% (P < 0.05) (at 1 and 12 h after i.v.
administration) (Fig. 8A, Table 1). It is known that SOD
activity may increase with the need of protection against
oxidant agents, such as vanadate. Apparently, only meta-
vanadate act as a prooxidant since decavanadate does
not induce the same overall response probably due to
diﬀerent reactivities that can result from diﬀerent
mechanisms. Concerning mitochondrial catalase (CAT)
activity, the basal CAT activity in mitochondria (1.63 ±
0.51 nmol/min/mg protein) (Table 1) decrease by 55%
(P < 0.05) 12 h after decavanadate exposure, whereas
metavanadate induced no signiﬁcant eﬀects (Fig. 8B). Putt-
ing it all together, 1 mM decavanadate in vivo administra-
tion diﬀers from metavanadate in not inducing cardiac
mitochondrial ROS production and SOD activity besides
decreasing catalase activity. Therefore, more pronounced
prooxidant eﬀects occur in cardiac mitochondria following
i.v. metavanadate exposure whereas decavanadate admin-
istration seems to prevent this eﬀect, probably by binding
to target proteins preventing its decomposition to vanadate
that induces the producing of reactive oxygen species or
due to diﬀerent reactivities.
The decrease on the activity of CAT by V10, is in agree-
ment to previous results from this laboratory, as we
reported that decavanadate induce a decrease in cardiac
mitochondrial catalase activity (60%), 7 days following
5 mM decavanadate i.p. administration in H. didactylus
[16]. Reduction of catalase activity was also described inB
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ctively. Variation is calculated based on basal values (Table 1). Values are
).
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was described that decavanadate and metavanadate admin-
istration clearly induce diﬀerent changes in oxidative stress
markers [20]. On the other hand, a previous study [16] con-
cluded that there are not any signiﬁcant changes in mito-
chondrial SOD activity in H. didactylus, 1 and 7 days
following i.p. exposure to 5 mM decavanadate or meta-
vanadate. Therefore, the antioxidants responses induced
by vanadate may depend on the total vanadium concentra-
tion administered, on the way of exposure and/or vary
between ﬁsh species, besides the vanadate species composi-
tion of vanadate solutions.
3.5. Concluding remarks
In contrast to metavanadate solutions containing sev-
eral labile oxovanadates species in equilibrium, decavana-
date solutions contain decameric vanadate species, whose
dissociation is slow enough to study its in vivo eﬀects.
The piscine models seem to be adequate to study the eﬀects
of the administration of decavanadate in antioxidant stress
markers, lipid peroxidation and vanadium subcellular dis-
tribution, not only due to the physiological temperature
but also due to their sensitive to metal toxicity.
At early stage of exposure (1, 6 and 12 h) and at lower
vanadium concentration (1 mM), decavanadate has a dif-
ferent pattern of lipid peroxidation and it does not induce
the increase of ROS production and SOD activity, on the
contrary it decreases catalase activity, although does not
aﬀect vanadium distribution in comparison to metavana-
date. It is proposed that the administration of decameric
vanadate clearly induces diﬀerent biological responses than
other labile oxovanadates probably due to diﬀerent reactiv-
ities that can result from diﬀerent mechanisms, pointing
out the importance of taking in account the V10 species
in the evaluation of vanadate eﬀects.Acknowledgements
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